Tyrosine kinase inhibition in bone metabolism

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 5, 2000, Pages 541-548

  Missbach, M ^a   Altmann, E ^a   Susa, M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

c Src; Kinase inhibitors; Osteoporosis; Tyrosine kinase

Indexed keywords

AP 22161; CGP 62464; CGP 76030; CGP 76775; COLONY STIMULATING FACTOR 1; NVP AAK 980; PD 161570; PD 166285; PP 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

DRUG DESIGN; ENZYME INHIBITOR INTERACTION; ENZYME MECHANISM; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 0033770321     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
2. Osteopetrosis in src-deficient mice is due to an autonomous defect of osteoclasts
3. Osteoclasts express high levels of pp60(c-Src) in association with intracellular membranes
4. Histomorphometric and immuno-cytochemical studies of Src-related osteopetrosis
5. Osteoclasts express high levels of p60(c-Src), preferentially on ruffled border membranes
6. The catalytic activity of Src Is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility
7. Requirement of pp60(c-Src) expression for osteoclasts to form ruffled borders and resorb bone in mice
8. Evidence that c-Src is Involved in the process of osteoclastic bone resorption
9. Regulation, substrates and functions of Src
10. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of αvβ3 integrin, and phosphorylated by Src kinase
11. Tumor necrosis factor-α activation of nuclear transcription factor-κB in marrow macrophages is mediated by c-Src tyrosine phosphorylation of lκBα
12. Design of peptidomimetic ligands for the pp60(src) SH2 domain
13. Design, synthesis, and cocrystal structure of a non-peptide Src SH2 domain ligand
14. Src homology-2 domains: Structure, mechanisms and drug discovery
15. Progress in the development of inhibitors of SH2 domains
16. Potent dipeptide inhibitors of the pp60(c-src) SH2 domain
17. Structure-based design and synthesis of a novel class of Src SH2 inhibitors
18. Structure-activity relationship of a novel class of Src SH2 inhibitors
19. Structure-based design and solid-phase parallel synthesis of phosphorylated non-peptides to explore hydrophobic binding at the Src SH2 domain
20. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption
21. The role of 4-phosphonodifluoromethyl- and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands
22. Exploring the specificity pockets of two homologous SH3 domains using structure-based, split-pool synthesis and affinity-based selection
23. Exploring the leucine-proline-binding pocket of the Src SH3 domain using structure-based, split-pool synthesis and affinity-based selection
24. Discovery of a novel series of potent and selective substrata-based inhibitors of p60(c-src) protein tyrosine kinase: Conformational and topographical constraints in peptide design
25. The design, synthesis and activity of non-ATP competitive Inhibitors of pp60(c-src) tyrosine kinase. Part 1: Hydroxynaphthalene derivatives
26. The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 2: Hydroxyindole derivatives
27. Combinatorial target-guided ligand assembly: Identification of potent subtype-selective c-Src inhibitors
28. Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases
29. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T-cell activation
30. Synthetic inhibitors of the protein tyrosine kinase PP60(c-Src) inhibit bone resorption in vitro
31. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
32. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor
33. 2-Substituted aminopyrido[2,3-dJpyrimidine-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity
34. Substituted 5,7-diphenylpyrrolo[2,3-dJpyrimidines: Potent inhibitors of the tyrosine kinase c-Src
35. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo
36. Tyrosine kinase Src inhibitor CGP 76030 supressess rapid bone loss Induced by retinoic acid In rats
37. NVP-AAK980, a novel 6-phenylamino-2-alkylamino-purine derivative, potently inhibits the tyrosine kinase Src and bone resorption
38. Three-dimensional structure of the tyrosine kinase c-Src
39. Crystal structure of the Src family tyrosine kinase Hck
40. Crystal structures of c-Src reveal features of its autoinhibitory mechanism
41. Use of a pharmacophore model for the design of EGF-R tyrosine kinase Inhibitors: 4-(phenylamino)pyrazolo[3,4-d] pyrimidines
42. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor
43. Role of colony-stimulating factor-1 in bone metabolism
44. M-CSF: Hematopoietic growth factor or inflammatory cytokine?
45. Osteoclast molecular phenotyping by random cDNA sequencing
46. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor κB (RANK) receptors
47. Colony-stimulating factor-1 induces cytoskeletal reorganization and c-Src-dependent tyrosine phosphorylation of selected cellular proteins in rodent osteoclasts
48. Evidence for e functional association between phosphatidylinositol 3-kinase and c-Src in the spreading response of osteoclasts to colony-stimulating factor-1
49. Expression of Src family kinases and their putative substrates in the human preostaoclastic cell line FLG 29.1
50. Heterotrimeric G proteins as fluoride targets in bone
51. Fluoroaluminate induces activation and association of Src and Pyk2 tyrosine kinases in osteoblastic MC3T3-E1 cells
52. Integrins and signaling in osteoclast function
53. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B- and T-cell populations
54. Mice deficient In Abl are osteoporotic and have defects in osteoblast maturation
55. Benzodiazepinone derivatives, preparation method and intermediates therefore, use as medicines end compositions
56. Method of antagonizing the human Src SH2 domain
57. Pyrrolo[2,3-d]pyrimidines and their use